Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
  • Policy / Pricing

CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices

FDA

CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III

Policy / PricingRead full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

FDA

CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III

Policy / PricingRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters
Next: Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

Related Stories

  • Policy / Pricing

US launches probe of German ‘underpayment’ for medicines

pharminent June 19, 2026
  • Policy / Pricing

FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’

pharminent June 19, 2026
  • Policy / Pricing

German said to be backtracking on pharma rebate changes

pharminent June 16, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.